An orphan drug legislation system

0Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Orphan drugs are a treatment for rare diseases. From that, comes the importance of orphan drug development and discovery. For an orphan drug to be approved by the FDA, it does not have to be similar to any approved orphan drug. So chemists opinions are important to determine the probability of similarity. It is too hard to check all orphan drugs for any rare disease. It takes a long time and big effort, so we introduce in this study a system that classifies the orphan drugs according to their probability of structural similarity. It also compares between them and the unauthorized orphan drug to determine the closest orphan drug to it. That system helps chemists to study a certain orphan database using the five features. That system provides better results. It provides chemists with the clusters of orphan drugs after adding the drug that needs to be authorized to its cluster.

Cite

CITATION STYLE

APA

Aziz, A. A., Zein, M., Atef, M., Adl, A., Ghany, K. K. A., & Hassanien, A. E. (2015). An orphan drug legislation system. Advances in Intelligent Systems and Computing, 323, 389–399. https://doi.org/10.1007/978-3-319-11310-4_34

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free